EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

EASL Congress 2024

 

5-8 June, Milan
Close
N. Poster
Poster title
Applicant name
Status
  TOP-003 Model for end-stage liver disease score-based liver allocation is associated with reduced survival in low donation countries a comparative analysis between Germany and the USA Leke Wiering Received Received
  TOP-012 Validation of transient elastography and the enhanced liver fibrosis test as prognostic biomarkers across the spectrum of steatotic liver disease Nikolaj Torp Received Received
  WED-027 Long-term post-transplant emergence of metabolic syndrome is associated with gut microbial metabolites in urinary metabolomics Jane Cox Received Received
  SAT-028 The relationship between spleen stiffness and portal hypertension liver transplant patients Kanan Nuriyev Received Received
  SAT-030 A visual classification scale of biliary anastomotic strictures with per-oral cholangioscopy predicts outcomes in liver transplant recipients Andres Cardenas Received Received
  SAT-036 Impact of distance from liver transplant centre on outcomes following liver transplantation - an australian single centre study Simone Chin Received Received
  FRI-038 Silver-coating of tunneled peritoneal drainage system is associated with a lower incidence of peritonitis and device explantation Sarah Lisa Schütte Received Received
  FRI-039 Terlipressin therapy is associated with increased risk of colonization with multidrug-resistant bacteria in patients with decompensated cirrhosis MARCUS MÜCKE Received Received
  SAT-040 Is there a need to screen for ischemic heart disease in liver transplant candidates without coronary calcification on routine chest CT? Susan Fischer Received Received
  FRI-041 Evaluating the influence of human albumin infusions on the MELD and MELD-Na scores in patients hospitalized with an acute decompensation of cirrhosis: an ATTIRE trial analysis Nikolaj Torp Received Received
  FRI-042 Comparison of clinical outcomes among patients with refractory ascites and implantation of either Alfapump, tunneled peritoneal drainage system or transjugular intrahepatic portosystemic shunt Sarah Lisa Schütte Received Received
  WED-055 Effect of long-term treatment with Simvastatin and Rifaximin in mitochondrial and proinflammatory pathways in patients with decompensated cirrhosis. A single-cell RNA seq analysis in PBMCs Adriŕ Juanola Received Received
  WED-056 Activated cytotoxic T-cells in mesenteric lymph nodes limit systemic bacterial dissemination, inflammation, and disease progression in chronic liver injury Pinky Juneja Received Received
  WED-058 High shear stress induced PIEZO1 activation promotes cytoskeleton remodelling and a nuclear deformation develops pro-thrombotic microenvironment and contributes to portal hypertension Rajni Yadav Received Received
  FRI-059 Proton pump inhibitors are not associated with an increased risk of hepatic encephalopathy Simon Johannes Gairing Received Received
  WED-060 Type-I interferon shapes peritoneal immunity in cirrhosis, driving caspase-5-mediated progranulin release during spontaneous bacterial peritonitis Michael Rooney Received Received
  TOP-061 Whole blood thrombin generation improves the understanding of cirrhotic coagulopathy and predicts clinical outcomes in patients with cirrhosis: a prospective cohort study Alberto Zanetto Received Received
  TOP-064 Impact of bacterial infections on kidney function and survival in patients with decompensated cirrhosis and acute kidney injury worldwide analysis of the ICA-GLOBAL AKI study Adriŕ Juanola Received Received
  TOP-065 Outcomes of thromboelastography guided versus routine empirical or on-demand platelet transfusion in patients with liver cirrhosis and severe thrombocytopenia undergoing high-risk invasive percutaneous and vascular procedures: an open-label, randomized controlled trial Sagnik Biswas Received Received
  TOP-066 Development and validation of a prognostic model (AMMON-AD) to define risk of overt hepatic encephalopathy in cirrhosis patients with acute decompensation María Pilar Ballester Received Received
  SAT-068 Accuracy of spleen stiffness measurement for the diagnosis of high-risk esophageal varices in patients with advanced chronic liver disease: a systematic review and individual patient data meta-analysis Elton Dajti Received Received
  WED-068 Cell-free DNA dynamics in advanced cirrhosis: unravelling the role of nuclear and mitochondrial DNA in inflammation, coagulation dysfunction and short-term mortality Marilena Stamouli Received Received
  WED-069 Bone morphogenic protein 9 (BMP9): a novel therapeutic agent for the prevention of extrahepatic organ failure in acute-on-chronic liver failure (ACLF) Alexandra Phillips Received Received
  WED-070 Isolation and immortalization of human endothelial cells from the portal vein Aina Anton Received Received
  TOP-072 Red blood cell distribution width-to-platelet ratio estimates the 3-year risk of decompensation in patients with metabolic dysfunction-associated steatotic liver disease-related cirrhosis Mario Romeo Received Received
  TOP-096 Glucagon-like peptide-1 receptor agonist, semaglutide attenuates liver cirrhosis-related skeletal muscle atrophy in diabetic mice Kosuke Kaji Received Received
  THU-100 Factors associated with the real-world biochemical response to fibrate therapy in primary biliary cholangitis Maria van Hooff Received Received
  THU-101 Non-invasive assessment of portal hypertension in patients with primary biliary cholangitis is affected by severity of cholestasis Ciro Celsa Received Received
  THU-102 Specific glycomic profiles can identify patients at risk of poor transplant-free survival in primary biliary cholangitis Nicky Somers Received Received
  SAT-105 Neutrophil extracellular traps are not linked to the development of decompensation, ACLF, or death in clinically stable patients with advanced chronic liver disease Lorenz Balcar Received Received
  SAT-106 Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) predicts acute-on-chronic liver failure in patients with acute decompensation Lorenz Balcar Received Received
  THU-106 Prospective european reference network registry (R-LIVER) supports improvement in bone disease care delivery at local level for patients with autoimmune liver diseases and enables detailed description of risk elements Boglarka Bozso Received Received
  THU-109 Increasing prevalence of primary biliary cholangitis in The Netherlands Rozanne de Veer Received Received
  SAT-117 Evaluation of Baveno VII criteria and other non-invasive tests for clinically significant portal hypertension in chronic hepatitis D Mathias Jachs Received Received
  FRI-118 Independent association of loss of skeletal muscle mass with long-term liver-related mortality in cirrhotic patients Jiarui Zheng Received Received
  FRI-127 The relationship between abnormal body composition by computed tomography imaging and long-term mortality in patients with cirrhosis Rui Huang Received Received
  FRI-131 Effect of adipose-related parameters on survival in patients with cirrhosis: a systematic review and meta-analysis Xinxing Tantai Received Received
  WED-131 Von Willebrand factor antigen reflects portal hypertension severity in porto-sinusoidal vascular disorder and predicts liver-related outcomes Lorenz Balcar Received Received
  FRI-132 Spontaneous bacterial empyema is a rare yet life-threatening complication in patients with hepatic hydrothorax Grace Wong Received Received
  WED-135 Impact of metabolic alterations on liver phenotype of patients with homozygous alpha-1 antitrypsin deficiency (Pi*ZZ) Christina Schrader Received Received
  TOP-141 Longitudinal assessment of individuals with homozygous alpha-1 antitrypsin deficiency (Pi*ZZ genotype) provides evidence for clinical patient management Malin Fromme Received Received
  TOP-142 Safety and efficacy of direct oral anticoagulants in cirrhotic and non-cirrhotic splanchnic vein thrombosis Lucia Giuli Received Received
  TOP-143 Porto-sinusoidal vascular disease among patients undergoing surgery for liver metastases: prevalence, non-invasive diagnosis, and burden on surgical outcomes Elton Dajti Received Received
  TOP-144 Heterozygosity for rare Apolipoprotein B variants predispose to severe metabolic associated steatotic liver disease Matteo Mureddu Received Received
  TOP-148 Interleukin-2 mediated regulatory T cell expansion is associated with dual outcomes of ductular reaction and liver fibrosis Man Chun Wong Received Received
  TOP-149 Plasmatic expression of miR122-5p and miR21-5p predicts relapse of autoimmune hepatitis after treatment withdrawal Pinelopi Arvaniti Received Received
  TOP-150 Molecular analysis of checkpoint inhibitor-induced liver injury Sarp Uzun Received Received
  SAT-151 The role of interleukin-8 in primary sclerosing cholangitis-associated immune cell dysregulation Lander Heyerick Received Received
  FRI-152 Gene editing to treat liver metabolic disorders: harnessing paired Cas9-Nickases for efficient and safe treatment of primary hyperoxaluria type 1 Laura Torella Received Received
  SAT-153 Single-cell RNA sequencing identifies the fundamental role of intrahepatic CD8 T cells in the pathogenesis of autoimmune hepatitis Ignasi Olivas Received Received
  SAT-154 Studying cholangiocyte properties and functions using a bile duct on a chip Henry Hoyle Received Received
  SAT-155 Impaired hepatic sympathetic neuronal communication intensifies hepatic inflammation, fibrosis and metabolic dysregulation, exacerbating liver injury sadam BHat Received Received
  WED-171 Spleen stiffness and VWF-based non-invasive tests reflect severity of prehepatic and presinusoidal portal hypertension Lorenz Balcar Received Received
  SAT-176 Itg-Cre/DTA mice develop the autoimmune biliary disease that serologically and pathogenically models human primary biliary cholangitis Jiaqi Zhang Received Received
  WED-190 Elevated hepatic copper content in porto-sinusoidal-vascular disorder: leading down a wrong track Lorenz Balcar Received Received
  FRI-194 Risk of all-cause mortality and adverse outcomes from steatotic liver disease and its subgroups in the general population Maurice Michel Received Received
  WED-198 Novel deep learning models utilising domain adaptation outperform conventional statistical models for predicting the risk of liver-related complications in patients with metabolic dysfunction-associated steatotic liver disease Terry Cheuk-Fung Yip Received Received
  TOP-228 CD36-mediated hepatocyte-macrophage coordination drives hepatic fibrosis in NAFLD Zhe Dai Received Received
  TOP-229 The E2F2 target glycerophosphodiester phosphodiesterase domain containing 3 is involved in MASLD progression to HCC and related dyslipidemias Maider Apodaka Biguri Received Received
  WED-231 Machine learning-based mortality prediction models for non-alcoholic fatty liver disease in the general United States population Jiarui Zheng Received Received
  FRI-234 Association between the duration of comorbidities and steatotic liver disease HA IL KIM Received Received
  TOP-241 Longitudinal changes in liver stiffness measurements in a population-based screening cohort of 5,517 participants Katrine Bech Received Received
  WED-249 Improved risk stratification by combination of FIB-4 with FGF21 serum levels in steatotic liver disease Heike Bantel Received Received
  THU-249 The role of the ferroptosis brake glutathione peroxidase 4 in a preclinical model of metabolic dysfunction-associated steatohepatitis Wilhelmus Kwanten Received Received
  TOP-252 Longitudinal changes in FIB-4 do not predict outcomes in patients with metabolic dysfunction-associated steatotic liver disease Hannes Hegmar Received Received
  WED-257 FibroScan compared to liver biopsy for accurately detecting recurrent hepatic steatosis and fibrosis after liver transplantation for metabolic dysfunction-associated steatohepatitis Laura Martínez-Arenas Received Received
  SAT-260 Metadoxine improves alcohol abstinence and is related to a lower risk of decompensation in cirrhosis at a median five-year follow-up: propensity score matching analysis Fatima Higuera Received Received
  WED-266 Age impacts the diagnostic ability of the enhanced liver fibrosis test for advanced fibrosis in MASLD Katrina Pekarska Received Received
  TOP-276 Time-trends of fibrosis and steatosis in metabolic dysfunction-associated steatotic liver disease (MASLD): a retrospective cohort analysis Umang Arora Received Received
  TOP-277 Liver fibrosis assessed via non-invasive tests is associated with incident heart failure in a general population cohort: a UK Biobank study Theresa Hydes Received Received
  FRI-298 Insulin resistance and sarcopenia as comorbid conditions in patients with MASLD Kateryna Pivtorak Received Received
  SAT-302 Long-term trends in the prevalence of alcohol-related cirrhosis among national U.S. veterans affairs data and territory wide Hong Kong data an east-west perspective Robert Wong Received Received
  TOP-311 Subtypes of steatotic liver disease have differing clinical outcomes Katrina Pekarska Received Received
  FRI-318 NGFR inhibition by TAT-Pep5 protects mice from acetaminophen-induced liver injury Laura Kitto Received Received
  WED-318 Steatotic liver disease in diabetic patients: more serious diabetes mellitus, more serious liver disease Zülal &304;stemihan Received Received
  WED-320 Optimizing non-alcoholic fatty liver disease care using mac-2 binding protein glycosylation isomer and correlations with advanced diagnostics Minh Khue Nguyen Received Received
  FRI-324 Advancing in drug-induced liver injury models development: high content screening in cell-based models derived from skin tissues Antonio Segovia-Zafra Received Received
  TOP-329 Integrated plasma multi-omics analysis classifies key mycobiome, microbiome and metabolome changes linked to development of poor outcome in severe alcoholic hepatitis GAURAV TRIPATHI Received Received
  SAT-338 Using retrieval augmented generation to increase large language models accuracy: a proof-of-concept pipeline on european hepatitis C virus (HCV) guidelines Mauro Giuffre Received Received
  TOP-344 Identifying spontaneous recovery in acute liver failure; a machine learning model Xun Zhao Received Received
  TOP-346 Therapeutic plasma exchange in Amatoxin associated acute liver failure results from an interim analysis of the Amanita-PEX study Dr. Bahar Nalbant Received Received
  FRI-348 Endogenous Annexin A1 has a protective effect on the liver in a diabetic mouse model Diego Dias dos Santos Received Received
  TOP-349 Plasma lipidomics and fungal peptide-based community analysis identifies signatures of severity and early mortality in acute liver failure Neha Sharma Received Received
  TOP-350 Differential DNA methylation as a potential drug-induced liver injury biomarker and genome-wide DNA methylation functional analysis Marina Villanueva Received Received
  TOP-351 A dual therapeutic strategy for acute liver failure: SIRP&945;-expressing extracellular vesicles from engineered mesenchymal stem cells for resolving CD47 in necroptotic hepatocytes and delivering regenerative cargo Seohyun Kim Received Received
  TOP-352 Serum proteomics can help identify new prognostic biomarkers in adults with acute liver failure Katharina Remih Received Received
  TOP-355 T cells expressing HBV-specific chimeric antigen receptors harboring a Fab fragment control HBV infection in mice Zhe Xie Received Received
  TOP-358 Non-HAP CAM-A ALG-006746 and ALG-006780 induce rapid HBsAg reductions in AAV-HBV mice and have favorable pharmacokinetic profiles Yannick Debing Received Received
  TOP-359 Development of a replication-competent Vesicular Stomatitis Virus (VSV) vector for therapeutic hepatitis B vaccination Jinpeng Su Received Received
  FRI-361 Burden of liver disease progression in patients with chronic HDV infection: a population-based study for France Lucia Parlati Received Received
  FRI-362 Hepatitis B surface antigen (HBsAg) seroclearance following discontinuation of nucleos(t)ide analogues (NA) treatment has comparable durability to HBsAg seroclearance achieved during NA therapy Terry Cheuk-Fung Yip Received Received
  FRI-363 Association between metabolic comorbidities, severity of liver fibrosis and fibrosis regression in patients with chronic hepatitis B an individual patient data meta-analysis Lisa van Velsen Received Received
  SAT-365 Hepatitis B virus mutations associated with hepatocellular carcinomas are regulated by HLA genotype Masaya Sugiyama Received Received
  FRI-367 Prediction of hepatocellular carcinoma risk and liver-related events in chronic hepatitis D, an international retrospective cohort study (RIDE) Lesley Patmore Received Received
  TOP-369 HEV replication and genomic diversification in the human kidney André Gömer Received Received
  FRI-373 Impact of pregnancy on global and HBV-specific B-cell immunity Anna Pocurull Received Received
  THU-378 Prediction of outcomes in patients with HCV compensated liver cirrhosis after SVR: results from 5-years of follow-up Luisa Ranieri Received Received
  SAT-379 Immune checkpoint proteins are associated with persistently elevated liver stiffness after successful HCV therapy in people with HIV Rubén Martín Escolano Received Received
  TOP-384 Macrophage-augmented organoids recapitulate the complex pathophysiology of viral diseases affecting the liver and devise advanced treatment strategies Kuan Liu Received Received
  TOP-385 Evaluation of liver fibrosis in patients with advanced chronic liver disease due to hcv after 6 years of sustained viral response. study with paired biopsies at 3 and 6 years Lidia Canillas Alavés Received Received
  FRI-389 Hepatitis delta virus infection is associated with significantly greater incidence of cirrhosis and hepatic decompensation in U.S. veterans with chronic hepatitis B Robert Wong Received Received
  TOP-401 Improvement of liver stiffness during nucleo(s)tide analogue treatment in patients with chronic hepatitis B and advanced fibrosis is not associated with a reduction in hepatocellular carcinoma risk Lesley Patmore Received Received
  WED-402 Risk of hepatocellular carcinoma after curative treatment when switching from Tenofovir Disoproxil Fumarate or Entecavir to Tenofovir Alafenamide: a real-world multicenter cohort study Hyunjae Shin Received Received
  THU-407 A new pattern for hepatitis C management in hospital: establishment and effectiveness verification Siheng Zhu Received Received
  SAT-407 Long-term sustained decline of anti-HCV neutralizing antibodies in HIV/HCV-coinfected patients after therapy-induced HCV clearance Daniel Sepúlveda-Crespo Received Received
  WED-413 10-year results under tenofovir disoproxil fumarate and entecavir in chronic hepatitis B; HBV clearance rare, disease outcomes good Zülal &304;stemihan Received Received
  WED-420 Evaluation of molnupiravir as an antiviral against hepatitis E virus infection Siddharth Sridhar Received Received
  SAT-425 Food swamps and easy access to unhealthy food increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) mortality in the United States (U.S.) Carey Escheik Received Received
  SAT-426 Prevalence and association between chronic kidney disease and steatotic liver disease in a nationally representative sample in the United States Mason Lai Received Received
  SAT-427 Hepatocellular carcinoma surveillance in the United Kingdom: a multi-centre study assessing uptake and inequalities Maria Qurashi Received Received
  WED-428 Patient, provider, and neighborhood-level factors associated with hepatitis delta testing in an academic health system Lauren Alpert Received Received
  WED-429 Hepatitis B virus care cascade in Rwanda: a population based-study Jean Damascene Makuza Received Received
  WED-438 Real-world based cost effectiveness analysis of entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy CHUN-TING HO Received Received
  WED-440 Community-based interventions to increase hepatitis B virus and hepatitic C virus infections screening among at-risk migrant and refugee populations in Italy, Greece, and Spain: 1-year results of the VH-COMSAVAC project CAMILA A PICCHIO Received Received
  WED-441 Precise estimation of national HBV prevalence: the importance of double hepatitis B surface antigen and hepatitis B core antibody testing in low endemic countries Arno Furquim dAlmeida Received Received
  WED-442 Decreasing trend of hepatitis C in homeless people between 2019-2023: a retrospective study in Madrid, Spain Daniel Sepúlveda-Crespo Received Received
  TOP-445 Associations of food insecurity and healthcare access with the prevalence and mortality of metabolic dysfunction-associated steatotic liver disease (MASLD): a global study of the United Nation and the global burden of disease data Carey Escheik Received Received
  FRI-456 Characterization of the intratumoral immune microenvironment of hepatocellular carcinoma before ive intrahepatic radiation therapy (SIRT) and study of its prognostic value on response to treatment Maria Stella Franzč Received Received
  THU-458 No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC Francisca Copil Received Received
  FRI-459 Outcome of targeting ATR in high replication stress murine HCC JING FANG Received Received
  THU-459 Long-term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma: a multicentric retrospective study Clémentine ALITTI Received Received
  TOP-460 Progression of hepatitis B virus (HBV)-related liver disease in immune-tolerant, inactive, and grey zone phases: a systematic review & meta-analysis Zakary Warsop Received Received
  TOP-461 Retreating the off-Nuc clinical relapse with Pegylated interferon much increased HBsAg seroclearance a propensity score matching study Yu-Ting Kao Received Received
  FRI-462 Aminoacyl-tRNA synthetases characterization and clinical potential in aggressive hepatocellular carcinoma Natalia Hermán-Sánchez Received Received
  FRI-463 Identifying unique cell states in early liver oncogenesis with transcription coupled repair Elizabeth Carmichael Received Received
  FRI-464 Caspases compromise SLU7 and UPF1 stability and nonsense-mediated RNA decay activity during hepatocarcinogenesis Carmen Berasain Received Received
  FRI-466 Implications and therapeutic potential of neddylation for pediatric liver cancer: hepatoblastoma Leidy Estefanía Zapata-Pavas Received Received
  THU-466 Treatment with Atezolizumab-Bevacizumab for hepatocellular carcinoma in the french population outside clinical trials: data from the prospective CHIEF cohort Manon Allaire Received Received
  FRI-467 Efficacy of WNTinib, a novel ive therapeutic for CTNNB1 mutant tumors, in preclinical models of hepatoblastoma Ugne Balaseviciute Received Received
  FRI-470 Deciphering the role of FXR in the rewiring of Treg polarization in hepatocellular carcinoma Yasmeen Attia Received Received
  SAT-474 Lesions hyper- to isointense to the surrounding liver in the hepatobiliary phase of gadoxetic acid enhanced MRI Alicia Furumaya Received Received
  SAT-477 The impact of etiology on patterns of progression of advanced HCC Bernardo Stefanini Received Received
  SAT-484 Conventional and machine-learning based risk score on survival for patients with hepatocellular carcinoma CHUN-TING HO Received Received
  TOP-488 Fecal microbiota transplant combined with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab interim analysis of the FAB-HCC phase II pilot study Katharina Pomej Received Received
  TOP-489 Predicting post-hepatectomy liver failure in patient with hepatocellular carcinoma: nomograms based on deep learning-analyzed gadoxetic acid-enhanced hepatobiliary phase images Boryeong Jeong Received Received
  SAT-497 A risk prediction model for hepatocellular carcinoma in general population without traditional risk factors for liver disease Byeong Geun Song Received Received
  TOP-507 Single-cell RNA sequencing-derived gene signatures reveal distinct response mechanisms to atezolizumab bevacizumab in advanced hepatocellular carcinoma Sarah Cappuyns Received Received
  TOP-509 Validation and improvement of the IMbrave050 criteria for high-risk of HCC-recurrence as an indication to adjuvant treatment: results from a 4-year retrospective competitive-risk study Federico Ravaioli Received Received
  TOP-511 Trends and evolution of hepatocellular carcinoma due to etiological shift from 2005 to 2020 in Germany: nationwide population-based study Josune Cabello Calleja Received Received
  SAT-515 Cholangiocarcinoma across England: evidence of regional, socioeconomic, and temporal variations in incidence, survival, routes to diagnosis and treatment Shahid Khan Received Received
  WED-518 Protein-modulated microbiota for fecal transplantation improves metabolic functions in alcohol-related liver disease model Nishu . Received Received
  TOP-520 Machine learning for risk stratification of hepatocellular carcinoma Jan Clusmann Received Received
  SAT-531 Testosterone modulates T cells in healthy individuals and women with autoimmune liver disease Nico Will Received Received
  SAT-532 Distinct soluble and cellular immunological signatures in various entities of hepatitis flares Roni Souleiman Received Received
  SAT-534 Macrophage-derived IL-15 imprints peritoneal tissue-resident memory T cells during spontaneous bacterial peritonitis in patients with cirrhosis Oluwatomi Ibidapo-obe Received Received
  SAT-535 The role of the immune checkpoint TIGIT in CD4 T cell dysfunction in patients with decompensated cirrhosis Joseph Delo Received Received
  FRI-547 Regenerative matrix-based hydrogels repair hepatocellular damage and promote cellular proliferation in pre-clinical models of acute liver injury Ashwini Vasudevan Received Received
  TOP-552 Oncogenic beta-catenin uses CD155 as a molecular actor to corrupt immunosurveillance of cold HCC Joana Gonalves Araujo Received Received
  FRI-555 New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: a human and experimental study Matias A Avila Received Received
  TOP-561 Butyrate induces epigenetic and metabolic reprogramming in myeloid-derived suppressor cells to alleviate primary biliary cholangitis Rui Wang Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
13:39
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

EASL Congress 2024

 

5-8 June, Milan
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 05/06/2024 TO 05/06/2025
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.EASL2024.2024 




PosterSessionOnline
Logo Draft
 
Logo Cert